JP2017516786A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516786A5 JP2017516786A5 JP2016569639A JP2016569639A JP2017516786A5 JP 2017516786 A5 JP2017516786 A5 JP 2017516786A5 JP 2016569639 A JP2016569639 A JP 2016569639A JP 2016569639 A JP2016569639 A JP 2016569639A JP 2017516786 A5 JP2017516786 A5 JP 2017516786A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- seq
- amino acid
- antigen
- hvr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000282567 Macaca fascicularis Species 0.000 claims description 11
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 1
- 239000000427 antigen Substances 0.000 description 26
- 102000036639 antigens Human genes 0.000 description 26
- 108091007433 antigens Proteins 0.000 description 26
- 150000001413 amino acids Chemical class 0.000 description 13
- 230000002163 immunogen Effects 0.000 description 7
- 210000000265 leukocyte Anatomy 0.000 description 4
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000003398 denaturant Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14170140.9 | 2014-05-28 | ||
| EP14170140 | 2014-05-28 | ||
| EP14180572.1 | 2014-08-11 | ||
| EP14180572 | 2014-08-11 | ||
| PCT/EP2015/061457 WO2015181098A1 (en) | 2014-05-28 | 2015-05-22 | Antibodies binding to human and cynomolgus cd3 epsilon |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017516786A JP2017516786A (ja) | 2017-06-22 |
| JP2017516786A5 true JP2017516786A5 (enExample) | 2020-07-09 |
| JP6738285B2 JP6738285B2 (ja) | 2020-08-12 |
Family
ID=53268799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016569639A Expired - Fee Related JP6738285B2 (ja) | 2014-05-28 | 2015-05-22 | ヒト及びカニクイザルｃｄ３イプシロンに結合する抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20170233475A1 (enExample) |
| EP (2) | EP3763739A1 (enExample) |
| JP (1) | JP6738285B2 (enExample) |
| KR (1) | KR20170003591A (enExample) |
| CN (1) | CN106459201A (enExample) |
| AU (1) | AU2015266077A1 (enExample) |
| BR (1) | BR112016022819A2 (enExample) |
| CA (1) | CA2942453A1 (enExample) |
| IL (1) | IL247740A0 (enExample) |
| MX (1) | MX2016015389A (enExample) |
| RU (1) | RU2016151235A (enExample) |
| SG (1) | SG11201609950YA (enExample) |
| WO (1) | WO2015181098A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL313608A (en) | 2015-12-09 | 2024-08-01 | Hoffmann La Roche | Antibody against CD20 type II to reduce the formation of antibodies against drugs |
| WO2017150762A1 (ko) * | 2016-02-29 | 2017-09-08 | (주)메디톡스 | 항-CD3γε 항체 및 이의 용도 |
| EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| CN118126180A (zh) * | 2016-12-22 | 2024-06-04 | 第一三共株式会社 | 抗cd3抗体和包含所述抗体的分子 |
| EP3409322A1 (en) | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| JP2020521791A (ja) | 2017-06-02 | 2020-07-27 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんの治療のためのｉｉ型抗ｃｄ２０抗体及び抗ｃｄ２０／ｃｄ３０二重特異性抗体 |
| WO2018224441A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
| US11319371B2 (en) | 2017-06-05 | 2022-05-03 | Numab Therapeutics AG | Anti-CD3 antibodies |
| JP7009517B2 (ja) | 2017-06-21 | 2022-01-25 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体 |
| US12486325B2 (en) | 2017-09-21 | 2025-12-02 | WuXi Biologics Ireland Limited | Anti-CD3epsilon antibodies |
| CN111108119B (zh) * | 2017-09-21 | 2022-11-15 | 上海药明生物技术有限公司 | 新型抗CD3ε抗体 |
| EP3717632B1 (en) | 2017-11-30 | 2022-10-26 | F. Hoffmann-La Roche AG | B-cell cultivation method |
| CN120399075A (zh) * | 2018-03-14 | 2025-08-01 | 诺维莫尼公司 | 抗-CD3ε抗体及其应用方法 |
| BR112020023508A2 (pt) * | 2018-05-24 | 2021-03-30 | Janssen Biotech, Inc. | Anticorpos anti-cd3 e usos dos mesmos |
| TW202016144A (zh) * | 2018-06-21 | 2020-05-01 | 日商第一三共股份有限公司 | 包括cd3抗原結合片段之組成物及其用途 |
| CN115916818A (zh) | 2019-12-11 | 2023-04-04 | 库利南肿瘤股份有限公司 | 抗cd19抗体和多特异性结合蛋白 |
| PE20230389A1 (es) * | 2020-05-27 | 2023-03-06 | Janssen Biotech Inc | Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas |
| JP7851303B2 (ja) * | 2020-09-24 | 2026-04-24 | モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ヒトｃｄ３イプシロンに結合する新規なヒト抗体 |
| CN114656562B (zh) * | 2020-12-23 | 2023-11-03 | 北京天广实生物技术股份有限公司 | 结合人和猴cd3的抗体及其应用 |
| WO2022175255A2 (en) | 2021-02-16 | 2022-08-25 | Janssen Pharmaceutica Nv | Trispecific antibody targeting bcma, gprc5d, and cd3 |
| US12258406B2 (en) | 2021-03-24 | 2025-03-25 | Twist Bioscience Corporation | Antibodies that bind CD3 Epsilon |
| CA3213632A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| WO2022228706A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
| CN115536740A (zh) * | 2021-06-30 | 2022-12-30 | 苏州方德门达新药开发有限公司 | 介导细胞内有效滞留cd3的空间构象表位及其应用 |
| CN113755435B (zh) * | 2021-10-15 | 2023-10-13 | 苏州药明康德新药开发有限公司 | 一种食蟹猴pbmc分离方法 |
| WO2023183766A1 (en) * | 2022-03-20 | 2023-09-28 | Abcellera Biologics Inc. | Anti-cd3 antibodies and t-cell engagers and methods of use |
| JP2025513714A (ja) * | 2022-03-22 | 2025-04-30 | モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｃｄ３に特異的な脱免疫抗体 |
| US20230414750A1 (en) | 2022-03-23 | 2023-12-28 | Hoffmann-La Roche Inc. | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
| WO2023198727A1 (en) | 2022-04-13 | 2023-10-19 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| WO2026006495A1 (en) | 2024-06-25 | 2026-01-02 | Alloy Therapeutics, Inc. | Anti-wt1/hla-a2 antibody and uses thereof |
| WO2026006492A2 (en) | 2024-06-25 | 2026-01-02 | Ypsilon Therapeutics, Inc. | Anti-prame/hla-a2 antibodies and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD272473B3 (de) * | 1988-06-13 | 1993-01-21 | Univ Leipzig | Verfahren zur herstellung monoklonaler antikoerper gegen die epsilon-kettedes cd 3-antigens humaner t-lymphozyten |
| JPH0630786A (ja) * | 1992-07-14 | 1994-02-08 | Kyowa Hakko Kogyo Co Ltd | バイスペシフィック抗体 |
| SG188175A1 (en) * | 2004-06-03 | 2013-03-28 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
| US8236308B2 (en) * | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
| SI2155788T1 (sl) * | 2007-04-03 | 2012-11-30 | Amgen Res Munich Gmbh | Bispecifični vezavni element specifičen za križane vrste |
| JP6400470B2 (ja) * | 2011-05-16 | 2018-10-03 | ジェネロン（シャンハイ）コーポレイション リミテッド | 多重特異性Ｆａｂ融合タンパク質および使用法 |
| WO2012162067A2 (en) * | 2011-05-21 | 2012-11-29 | Macrogenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
| US20170073415A1 (en) * | 2014-05-12 | 2017-03-16 | Numab Ag | Novel multispecific molecules and novel treatment methods based on such multispecific molecules |
-
2015
- 2015-05-22 CN CN201580026998.5A patent/CN106459201A/zh active Pending
- 2015-05-22 AU AU2015266077A patent/AU2015266077A1/en not_active Abandoned
- 2015-05-22 MX MX2016015389A patent/MX2016015389A/es unknown
- 2015-05-22 SG SG11201609950YA patent/SG11201609950YA/en unknown
- 2015-05-22 KR KR1020167033022A patent/KR20170003591A/ko not_active Withdrawn
- 2015-05-22 EP EP20163877.2A patent/EP3763739A1/en not_active Withdrawn
- 2015-05-22 BR BR112016022819A patent/BR112016022819A2/pt not_active Application Discontinuation
- 2015-05-22 JP JP2016569639A patent/JP6738285B2/ja not_active Expired - Fee Related
- 2015-05-22 WO PCT/EP2015/061457 patent/WO2015181098A1/en not_active Ceased
- 2015-05-22 RU RU2016151235A patent/RU2016151235A/ru not_active Application Discontinuation
- 2015-05-22 CA CA2942453A patent/CA2942453A1/en not_active Abandoned
- 2015-05-22 EP EP15725002.8A patent/EP3149041A1/en not_active Ceased
-
2016
- 2016-09-11 IL IL247740A patent/IL247740A0/en unknown
- 2016-11-22 US US15/359,199 patent/US20170233475A1/en not_active Abandoned
-
2020
- 2020-01-23 US US16/751,046 patent/US20200325224A1/en not_active Abandoned
- 2020-01-23 US US16/751,062 patent/US20200299385A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016151235A (ru) | Антитела, связывающиеся с cd3 эпсилон человека и обезьян циномолгус | |
| PH12018500708A1 (en) | Humanized anti-human cd19 antibodies and methods of use | |
| PE20201186A1 (es) | Anticuerpos antitau y metodos de uso | |
| ES2685424T3 (es) | Anticuerpos anti-Jagged1 y procedimientos de uso | |
| PE20150025A1 (es) | Anticuerpos e inmunoconjugados contra ly6e y metodos de uso | |
| PE20161571A1 (es) | Anticuerpos anti-ox40 y metodos de uso | |
| RU2017104642A (ru) | Новое антитело против tie-2 человека | |
| JP2013538057A5 (enExample) | ||
| NZ592119A (en) | Anti-pd-l1 antibodies and their use to enhance t-cell function | |
| PE20141562A1 (es) | Anticuerpos anti-htra1 y metodos de uso | |
| PE20120553A1 (es) | Anticuerpos anti-fgfr3 | |
| EP4252769A3 (en) | Anti-complement factor c1q antibodies and uses thereof | |
| PE20181336A1 (es) | Anticuerpos que se unen a interleucina 8 (il-8) y sus usos | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| JP2014526898A5 (enExample) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| RU2017125758A (ru) | Антитела к с5 и способы их применения | |
| NZ603226A (en) | Anti-c5a antibodies and methods for using the antibodies | |
| PE20181402A1 (es) | Anticuerpos anti-c5 y metodos de uso | |
| AR096364A1 (es) | Anticuerpos receptores de antitransferina y métodos de uso | |
| RU2016110891A (ru) | Антитела к fcrh5, их иммуноконъюгаты и способы их применения | |
| JP2016512034A5 (enExample) | ||
| NZ626520A (en) | Anti-lrp5 antibodies and methods of use | |
| JP2017502695A5 (enExample) | ||
| RU2016107814A (ru) | Новое антитело к tslp-рецептору человека |